Drug reference

Eptifibatide

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 245

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

In combination with aspirin and unfractionated heparin for the prevention of early myocardial infarction in patients with unstable angina or non-ST-segment- elevation myocardial infarction and with last episode of chest pain within 24 hours (specialist use only) ▶INITIALLY BY INTRAVENOUS INJECTION ▶Adult: Initially 180 micrograms/kg, then (by intravenous infusion) 2 micrograms/kg/minute for up to 72 hours (up to 96 hours if percutaneous coronary intervention during treatment)

PDF page 245

Contra Indications

Abnormal bleeding within 30 days. haemorrhagic diathesis. history of haemorrhagic stroke. increased INR. increased prothrombin time. intracranial disease. major surgery or severe trauma within 6 weeks. severe hypertension. stroke within last 30 days. thrombocytopenia

PDF page 245

Cautions

Discontinue if emergency cardiac surgery necessary. discontinue if intra-aortic balloon pump necessary. discontinue if thrombolytic therapy necessary. risk of bleeding—discontinue immediately if uncontrolled serious bleeding

PDF page 245

Safety

Interactions

→Appendix 1: eptiﬁbatide

PDF page 245

Side Effects

▶Common or very common Arrhythmias. atrioventricular block. cardiac arrest. congestive heart failure. haemorrhage. hypotension. intracranial haemorrhage. procedural complications. shock ▶Uncommon Cerebral ischaemia. thrombocytopenia ▶Rare or very rare Rash Cardiovascular system

PDF page 245

Pregnancy

Manufacturer advises use only if potential beneﬁt outweighs risk—no information available.

PDF page 245

Breast Feeding

Manufacturer advises avoid—no information available.

PDF page 245

Hepatic Impairment

Manufacturer advises caution; avoid in signiﬁcant impairment (increased risk of bleeding complications, limited information available).

PDF page 245

Renal Impairment

Avoid if eGFR less than 30 mL/minute/1.73 m2. Dose adjustments Reduce infusion to 1 microgram/kg/minute if eGFR 30–50 mL/minute/1.73 m2.

PDF page 245

Monitoring Requirements

▶Measure baseline prothrombin time, activated partial thromboplastin time, platelet count, haemoglobin, haematocrit and serum creatinine. ▶Monitor haemoglobin, haematocrit and platelets within 6 hours after start of treatment, then at least once daily.

PDF page 245

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Solution for injection ▶Eptifibatide (Non-proprietary) Eptifibatide 2 mg per 1 ml Eptifibatide 20mg/10ml solution for injection vials | 1 vial P s (Hospital only) ▶Integrilin (GlaxoSmithKline UK Ltd) Eptifibatide 2 mg per 1 ml Integrilin 20mg/10ml solution for injection vials | 1 vial P £13.61 (Hospital only) Solution for infusion ▶Eptifibatide (Non-proprietary) Eptifibatide 750 microgram per 1 ml Eptifibatide 75mg/100ml solution for infusion vials | 1 vial P s (Hospital only) ▶Integrilin (GlaxoSmithKline UK Ltd) Eptifibatide 750 microgram per 1 ml Integrilin 75mg/100ml solution for infusion vials | 1 vial P £42.79 (Hospital only)

PDF page 245

Dose text by age group

Adult

Initially 180 micrograms/kg, then (by

First-line fragment. Read the complete Indications and Dose section above.

PDF page 245

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Eptifibatide

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 245

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 245

Contra Indications

PDF page 245

Cautions

PDF page 245

Safety

Interactions

→Appendix 1: eptiﬁbatide

PDF page 245

Side Effects

PDF page 245

Pregnancy

Manufacturer advises use only if potential beneﬁt outweighs risk—no information available.

PDF page 245

Breast Feeding

Manufacturer advises avoid—no information available.

PDF page 245

Hepatic Impairment

Manufacturer advises caution; avoid in signiﬁcant impairment (increased risk of bleeding complications, limited information available).

PDF page 245

Renal Impairment

Avoid if eGFR less than 30 mL/minute/1.73 m2. Dose adjustments Reduce infusion to 1 microgram/kg/minute if eGFR 30–50 mL/minute/1.73 m2.

PDF page 245

Monitoring Requirements

PDF page 245

Dose and formulations

Medicinal Forms

PDF page 245

Dose text by age group

Adult

Initially 180 micrograms/kg, then (by

First-line fragment. Read the complete Indications and Dose section above.

PDF page 245

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.